Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses: 2011-2021

Historic Other Accumulated Expenses for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Dec 2021 value amounting to $178,000.

  • Lineage Cell Therapeutics' Other Accumulated Expenses fell 90.00% to $1,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $1,000, marking a year-over-year decrease of 90.00%. This contributed to the annual value of $178,000 for FY2021, which is 1877.78% up from last year.
  • Lineage Cell Therapeutics' Other Accumulated Expenses amounted to $178,000 in FY2021, which was up 1,877.78% from $9,000 recorded in FY2020.
  • Lineage Cell Therapeutics' Other Accumulated Expenses' 5-year high stood at $178,000 during FY2021, with a 5-year trough of $4,000 in FY2019.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $9,000 (2020), whereas its average is $63,667.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Accumulated Expenses tumbled by 93.43% in 2018 and then surged by 1,877.78% in 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Accumulated Expenses (Yearly) stood at $137,000 in 2017, then plummeted by 93.43% to $9,000 in 2018, then tumbled by 55.56% to $4,000 in 2019, then spiked by 125.00% to $9,000 in 2020, then skyrocketed by 1,877.78% to $178,000 in 2021.